期刊文献+

细胞色素P450临床不合理用药分析 被引量:1

下载PDF
导出
摘要 目的阐述细胞色素P450在临床联合用药中的重要性,对临床不合理联合用药进行干预。方法对临床药师在查房中搜集到的典型的不合理用药案例中与细胞色素P450有关的病例进行用药分析。结果临床药师能及时发现、解决潜在的与细胞色素P450相关的不合理用药现象。结论通过临床药师的干预,确保临床用药的安全、有效、合理,促进药物合理使用,减少不良反应的发生。
作者 吴紫娟
出处 《临床合理用药杂志》 2011年第04X期69-69,共1页 Chinese Journal of Clinical Rational Drug Use
  • 相关文献

参考文献2

二级参考文献71

  • 1THOMPSON PD,CLARKSON P,KARAS RH.Statin-associated myopathy[J].JAMA,2003,289 (13):1681-1690.
  • 2DAVIDSON MH.Controversy surrounding the safety of cerivastatin[J].Expert Opin Drug Saf,2002,1 (3):207-212.
  • 3STAFFA JA,CHANG J,GREEN L.Cerivastatin and reports of fatal rhabdomyolysis[J].N Engl J Med,2002,346(7):539-540.
  • 4RATZBRAVO AE,TCHAMBAZ L,KRAHENBUHL-MELCHER A,et al.Prevalence of potentially severe drug-drug interaction in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy[J].Drug Saf,2005,28 (3):203-275.
  • 5BELLOSTA S,PAOLETTI R,CORSINI A,et al.Safety of statins:focus on clinical pharmacokinetics and drug interactions[J].Circulation,2004,109(23 Suppl 1):Ⅲ 50-Ⅲ 57.
  • 6KAJINAMI K,TAKEKOSHI N,SAITO YL.Pitavastatin:efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor[J].Cardiovasc Drug Rev,2003,21 (3):199-215.
  • 7McKENNEY JM.Efficacy and safety of rosuvastatin in treatment of dyslipidemia[J].Am J Health Syst Pharm,2005,62(10):1033-1047.
  • 8THOMPSON PD,LARKSON P,KARAS RH.Statin-associated myopathy[J].JAMA,2003,289 (13):1681-1690.
  • 9DAVIDSON MH,TOTH PP.Comparative effects of lipid-lowering therapies[J].Prog Cardiovasc Dis,2004,47(2):73-104.
  • 10HO LDAAS H,FELLSTROM B,JARDINE AG,et al.Effect of fluvastatin on cardiac outcomes in renal transplant recipients:a multicentre,randomised,placebo-controlled trial[J].Lancet,2003,361 (9374):2024-2031.

共引文献51

同被引文献22

  • 1Jankel CA,Speedie SM. Detecting drug interactions:a review of the literature[J].Dicp,1990,(10):982-989.
  • 2Gauthier I,Malone M. Drug-food interactions in hospitalized patients.Methods of prevention[J].Drug Safety,1998,(06):383-393.doi:10.2165/00002018-199818060-00001.
  • 3Horn JR,Hansten PD,Chan LN. Proposal for a New Tool to Evaluate Drug Interaction Cases[J].Annals of Pharmacotherapy,2007,(4):647-680.doi:10.1345/aph.1H423.
  • 4Yildirim Y,Ozyilkan O,Akcali Z. Drug interaction between capecitabine and warfarin:a case report and review of the literature[J].International Journal of Clinical Pharmacology Therapeutics,2006,(02):80-82.
  • 5Monastero R,Camarda R,Camarda C. Potential drug-drug interaction between duloxetine and acenocoumarol in a patient with Alzheimer' s disease[J].Clinical Therapeutics,2007,(12):2706-2709.doi:10.1016/j.clinthera.2007.12.026.
  • 6Gulbis AM,Culotta KS,Jones RB. Busulfan and metronidazole:an often forgotten but significant drug interaction[J].Annals of Pharmacotherapy,2011,(7-8):e39.doi:10.1345/aph.1Q087.
  • 7Hu M,Mak VW,Tomlinson B. Simvastatin-induced myopathy,the role of interaction with diltiazem and geuetic predisposition[J].Journal of Clinical Pharmacy and therapeutics,2011,(03):419-425.doi:10.1111/j.1365-2710.2010.01184.x.
  • 8Gomo C,Coriat R,Faivre L. Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma[J].Investigational New Drugs,2010.
  • 9Bilgi N,Bell K,Ananthakrishnan AN. Imatinib and Panax ginseng:a potential interaction resulting in liver toxicity[J].Annals of Pharmacotherapy,2010,(05):926-928.doi:10.1345/aph.1M715.
  • 10Mir O,Blanchet B,Goldwasser F. Drug-lnduced Effects on Erlotinib Metabolism[J].New England Journal of Medicine,2011,(04):379-380.doi:10.1056/NEJMc1105083.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部